antitumor and radiosensitizing properties of 5-bromo-2'-deoxyuridine (BUdR) appear to be due, in part, to its incorporation into cellular DNA. To optimize conditions for incorporation of 5-bromo-2'-deoxyuridine-S-monophosphate (BrdUMP) into DNA, we investigated the metabolism of BUdR to its DNA precursor form, the 5'-triphosphate BrdUTP, in the U251 human glioblastoma cell line. The results demonstrated that BrdUTP accumulated rapidly in this cell line, achieving steadystate values within 2 hr of drug addition. The level of BrdUTP accumulation was proportional to the amount of exogenous BUdR up to a concentration of lOOpM, without apparent saturation. Exposure of glioblastoma cells to BUdR was associated with substantial selective decreases in both the cellular dCTP and 'ITP pools, the extent of which was dependent on the exogenous BUdR concentration. In the absence of exogenous BUdR, BrdUTP was eliminated rapidly from cells with an initial half-life of approximately 15 min. As the cellular BrdUTP level declined, the dCTP and lTP levels increased to control values. Incorporation of BrdUMP into DNA appeared linear with time as long as the cellular BrdUTP level remained constant. This incorporation was not enhanced by the addition of 5-fluoro-2'-deoxyuridine (FUdR), a potent inhibitor of thymidylate synthetase, which at a concentration of 10 nM had no effect on 'ITP pools in this cell line. Thus, the decrease in cellular TTF' pools mediated by BrdUTP allows the halogenated pyrimidine to enhance its own incorporation into DNA.
5-Bromo-2'-deoxyuridine
(BUdRB) is a thymidine analog which is readily incorporated into the DNA of cells, bacteria and viruses as the 5'-monophosphate derivative (BrdUMP) [l, 21 . DNA incorporation of this fraudulent nucleotide is associated with diverse biologic activities, including antitumor and antiviral properties, mutagenic effects and the ability to increase the sensitivity of cells to radiation damage [l-3] . The radiosensitization effect has been exploited clinically by administering BUdR in conjunction with radiation therapy to patients with malignancies [4] . Glioblastomas are well-suited to treatment with BUdR since the rapidly dividing tumor cells should readily incorporate the halogenated analog whereas the slower dividing normal brain cells would be less vulnerable to the toxic effects of this agent. Initial attempts to administer BUdR during a prolonged infusion to patients were hampered by vascular and infectious complications, and myelosuppression limited the amount of BUdR that could be administered [5, 6] . The use of an implantable infusion pump to administer BUdR intraarterially has eliminated the vascular and infectious complications associated with prolonged intravenous infusion of this drug [7, 8] . Furthermore, the development of a rapid and sensitive assay system has permitted adjustment of the drug dose to maintain plasma concentrations of BUdR which are therapeutic but not myelosuppressive [8, 9] . Preliminary clinical results with the combination of BUdR and radiation therapy are encouraging [8, lo] .
Since BUdR must be incorporated into cellular DNA in order to act as a radiosensitizer, recent reports have examined the relationship between BUdR concentration and incorporation of its Smonophosphate into glioblastoma DNA both in vitro and in vivo [8,11]. The in vitro studies have demonstrated that the incorporation of BrdUMP into cellular DNA can vary significantly between cultured cell lines. However, the reason for this variation has not been elucidated. To be incorporated into DNA, BUdR must be metabolized intracellularly to 5-bromo-2'-deoxyuridine-5'-triphosphate (BrdUTP), the immediate DNA precursor. There are three distinct kinases responsible for this phosphorylation [2, 12] , and in addition BUdR and its phosphorylated metabolites can be degraded by other enzymes. Heterogeneity between cell lines at any one of these metabolic steps can lead to variable BrdUTP levels, resulting in differential DNA incorporation of this analog. Alternatively, the relative concentration of the competing endogenous TI'P pool may contribute to the heterogeneity of BrdUMP incorporation between cell lines. Despite the fact that the extent of BrdUMP incorporation is dependent on the ability of the cell to accumulate BrdUTP, the rate and extent of accumulation of this metabolite have not been well studied. Evaluation of the cellular metabolism of BUdR may identify cell-specific differences which result in variable DNA incorporation of this analog and, furthermore, such studies may suggest new methods for increasing the amount of BrdUMP incorporated into DNA to produce greater cytotoxicity and radiosensitization. Thus, the data presented here describe the metabolism of BUdR in glioblastoma cells in culture. We also report the effects of S-fluoro-2'-deoxyuridine (FUdR), a potent inhibitor of thymidylate synthetase, on this metabolism. A preliminary account of these studies has been presented [13] .
MATERIALS AND METHODS
Chemicals. RPM1 1640 cell culture medium and horse serum were obtained from GIBCO BRL (Grand Island, NY). Bovine calf serum was purchased from Hyclone (Logan, UT). Nucleosides and nucleotide standards were obtained from the Sigma Chemical Co. (St. Louis, MO). Ammonium phosphate buffer was purchased from J. T. Baker Inc. (Phillipsburg, NJ). All other chemicals were reagent grade.
Cells. U251 glioblastoma cells were a gift from Dr. Dare11 Bigner, Duke University Medical Center [ 141. The cells were maintained as monolayer cultures in RPM1 1640 medium supplemented with 10% bovine calf serum. It was determined that less than 0.1 ,uM thymidine was present in the serum. Cells used in the experiments described here were passaged at least 3 days prior to the beginning of the study to ensure that the population was in exponential growth at the time of drug addition.
To harvest the cells for nucleotide analysis, medium from the cultures was poured off rapidly and the plate was washed once with phosphatebuffered saline (PBS). Trypsin was added (0.25%) to detach the cells from the plate, at which point ice-cold PBS with 10% horse serum was added rapidly to stop the trypsinization process. An aliquot of the well-dispersed cell suspension was removed for estimation of cell number using an electronic particle counter (Coulter Electronics, Hialeah, FL), and the remainder was centrifuged at -4". The cell pellet was then extracted with 0.4 N perchloric acid and neutralized with potassium hydroxide to isolate the acid-soluble nucleotides. The cell extract was stored at -20" until analysis.
Nucleotide analysis. For analysis of cellular deoxyribonucleotides, the cell extract was first separated on a boronate affinity column to remove the majority of the ribonucleotides.* Deoxyribonucleotides were then analyzed using a Waters high pressure liquid chromatograph equipped with a U6K injector, two model 501 pumps and a model 490 four-channel absorbance detector. The system was controlled by means of Maxima 820 software operated on a NEC Powermate 2 computer. The deoxyribonucleotides from the extract were loaded onto a strong anion exchange column * Manuscript in preparation.
(Whatman, NJ) and eluted with a linear gradient of ammonium phosphate buffer ranging in concentration from 0.15 to 0.6 M. The pH of the buffer was varied from 3.5 to 4.1. Nucleotides were identified based on their UV absorbance at 254,281 and292 nmandcomigrationwithauthenticstandards. Nucleotides in cell extracts were quantitated by comparison of their peak areas with that of a known amount of the appropriate standard.
Incorporation of BrdUMP into DNA. Cells were incubated with BUdR and trypsinized rapidly as described above. Between 2 x lo6 and 5 x lo6 cells were aliquotted routinely for estimation of BrdUMP incorporation and processed by a previously reported procedure [15, 16] . Briefly, cells were lysed and treated with proteinase K. DNA was then isolated by phenyl/chloroform-isoamyl alcohol extraction followed by ethanol precipitation. The DNA was hydrolyzed to individual bases by treatment with DNAse I, snake venom phosphodiesterase, alkaline phosphatase and thymidine phosphorylase.
The bases were extracted into ethyl acetate, derivatized with bis-trimethylsilyl trifluoroacetamide. Resulting products were then detected and quantitated using a Hewlett-Packard 5987A gas chromatograph/mass spectrometer in the selected ion monitoring mode.
Analysis of BUdR in the cell medium. Immediately prior to harvesting cells exposed to BUdR, an aliquot of the cell medium was removed and frozen at -20" for quantitation of the amount of BUdR remaining at that time. Thawed medium samples were diluted and then analyzed without further processing for their BUdR content by a standard HPLC procedure [91.
RESULTS

Accumulation
of BrdlJTP.
The time-and concentration-dependence of BrdUTP accumulation was assessed in U251 glioblastoma cells. Initial studies demonstrated that, with BUdR concentrations ranging from 2 to 20pM, BrdUTP accumulated rapidly, achieving steady-state values within 1 hr which were maintained for at least 8 hr after drug addition (data not shown). Furthermore, the exogenous concentration of BUdR remained unchanged for at least 6 hr following drug addition at concentrations in excess of 2pM. Hence, the relationship between BUdR concentration and BrdUTP accumulation was assessed in U251 cells during a 2-hr incubation period. When the exogenous BUdR concentration ranged from 1 to lOOpM, BrdUTP accumulated intracellularly in a linear fashion without apparent saturation (data not shown).
Effects of endogenous deoxyribonucleotide pools.
Since it has been reported that BUdR can result in inhibition of CDP reduction by ribonucleotide reductase [17] -. for at least 12 hr. Figure 1 illustrates the effects of this drug exposure on the endogenous deoxyribonucleoside triphosphate pools. The TTP and dCTP pools exhibited the greatest alterations, decreasing to 60 and 70% of their initial values, respectively. In contrast, the levels of dATP and dGTP remained relatively constant during this incubation. The decline in the TTP and dCTP values was most evident during the first 6 hr after BUdR addition, whereas between 6 and 25 hr these values decreased only slightly.
Metabolic effects after removal of BUdR from medium. To determine whether or not the observed decreases in dCTP and TTP pools were reversible, U251 cells were incubated with 20pM BUdR for 2 hr followed by replacement of the medium with fresh drug-free medium. Cells were harvested periodically and analyzed for nucleotide content. As illustrated in Fig. 3 , the levels of the dCTP and TTP pools increased following washout of the BUdR, attaining the initial untreated control value within 4 hr. Only minor changes in the dATP and dGTP pools were observed during this interval. Thus, the changes in the pyrimidine deoxyribonucleotide pools induced by BUdR were readily reversible following removal of the exogenous BUdR.
Other similar experiments have demonstrated In the same experiment described in Fig. 3 , the consistently that exposure of U251 cells to BUdR rate of decay of BrdUTP was assessed. As indicated resulted in a decline in TTP and dCTP pools, with in Fig. 4 , BrdUTP was eliminated rapidly from the little or no effect on the purine deoxyribonucleotide cells following removal of exogenous BUdR. The pools. This effect on pyrimidine deoxyribonucleotide rate of BrdUTP elimination was multiexponential, pools was exaggerated at higher BUdR concenwith the initial half-life calculated as approximately trations, and TTP pools were depressed consistently 15 min. One hour after removal of BUdR, the to a greater extent than dCTP pools. Figure 2 BrdUTP half-life increased to more than 2 hr. These illustrates the relationship between increasing BUdR concentrations and the endogenous 'lTP levels. Exposure to 20yM BUdR for 2 hr reduced TTP to approximately 40% of the untreated control value (Fig. 2) , whereas higher BUdR concentrations (up to 100pM) resulted in a decrease in TTP to approximately 10% of the control value (data not shown). At concentrations of BUdR as high as lOOpM, no significant perturbations in dATP or dGTP levels were observed (data not shown).
These studies demonstrate that BrdUTP can achieve an intracellular concentration that exceeds that of the endogenous deoxyribonucleoside triphosphates. Indeed, at 100 yM BUdR, BrdUTP can achieve a level more than five times higher than the TTP value. However, at the clinically achievable plasma concentration of 2 ,uM, BrdUTP is typically 5-to lo-fold lower than the endogenous TTP level. Analysis of the amount of BUdR remaining in the medium during the course of the experiment indicated that the drug remained at a constant level for at least the first 6 hr, but by 24 hr it had decreased to 0.18 PM. These data suggest that, in the presence of a constant exogenous BUdR concentration, U251 cells maintain a constant BrdUTP level which is associated with a continual increase of BrdUMP incorporation into DNA. However, degradation of the exogenous BUdR results in a decrease in the cellular BrdUTP concentration and a slower rate of incorporation of the analog into DNA.
Attempts to increase the DNA incorporation of BrdUMP have centered around adding agents which decrease endogenous TTP pools such as FUdR or FUra [2,3,11,18].
However, Mancini et al. [ll] have reported recently that the incorporation of BrdUMP into U251 cellular DNA during a 24-hr incubation with BUdR was not augmented by simultaneous exposure to FUdR. In an effort to elucidate the mechanism responsible for this lack of modulation by FUdR, we examined the effect of FUdR on the cellular levels of BrdUTP and TTP and, in the same cell population, measured the incorporation of BrdUMP into cellular DNA. We employed a 6-hr incubation period for these studies to expose the cells to a constant level of BUdR. Table 1 illustrates that, over a 6-hr time period, 10nM FUdR did not increase substantially the incorporation of BrdUMP into the DNA of U251 glioblastoma cells, in accord with previous results employing longer incubation periods [ll] . Table 2 demonstrates that FUdR did not decrease the cellular 'ITP pool level in these cells, nor did it affect the amount of BrdUTP that accumulated in these cells. Other experiments have demonstrated consistently that a 6-hr incubation of U251 cells with 10 nM FUdR does not depress 'ITP pools (data not shown). Thus, since the levels of 'ITP and BrdUTP were not altered by FUdR, this analog should have no effect on the incorporation of BrdUMP into DNA. It will be important to determine whether longer incubation periods or higher concentrations of FUdR are able to depress TTP pools in these cells and, if not, the mechanism by which U251 cells are insensitive to the nucleotide effects of FUdR must be elucidated.
DISCUSSION
While the exact mechanisms by which BUdR exerts its biologic effects are not known, it appears that several of these effects are due, in part, to its incorporation into cellular DNA [l, 21. Although this incorporation is dependent upon the intracellular conversion of BUdR to BrdUTP, there are few reports describing the rate and extent of accumulation of this important metabolite. Despite current interest in BUdR as adjunct therapy in patients with brain tumors, the data on the metabolism of BUdR in gliomas are sparse. Thus, we have investigated the metabolism of BUdR in a cultured glioblastoma cell line as a first step in the elucidation of the relevant biochemical parameters which determine the level of BrdUMP incorporation into DNA.
Thymidine kinase is the first enzyme in the metabolic pathway that converts BUdR to BrdUTP. BUdR is reported to be a good substrate for this enzyme, with projected K,,, values in the range of 2 to 3pM, similar to the Km value for the native substrate thymidine [19-211. In the data presented here, BrdUTP rapidly accumulated to a steady-state level, which may reflect a high affinity of thymidine kinase in the U251 cells for BUdR. These data also demonstrated that BrdUTP accumulation was not saturated at concentrations of BUdR as much as 50-fold above its putative K,,, value for thymidine kinase. This finding may be explained by the observation that the endogenous TTP level decreased substantially in response to BUdR exposure. Since TTP can act as a feedback inhibitor on thymidine kinase [22-241, However, our data indicate that BrdUTP at levels up to 544 pmol/lO' cells does not inhibit the phosphorylation of BUdR in the U251 line. It is likely that the interaction between the decreasing TTP levels and perhaps the presence of other cellular nucleotides prevent BrdUTP from significantly inhibiting thymidine kinase activity in the intact glioblastoma cells.
The results in Fig. 1 illustrate that exposure to BUdR results in a significant decrease in both the endogenous dCTP and 'ITP pool levels. Other investigators have also demonstrated that the cellular dCTP pools decrease during exposure to BUdR, apparently due to feedback inhibition of ribonucleotide reductase by BrdUTP [17, 25] . BrdUTP may be acting in a manner similar to dUTP which, according to the current models of regulation of ribonucleotide reductase, results in decreased production of both dCTP and TTP [26, 27] . Indeed, adding deoxyuridine to lymphoid cells in culture can produce reductions in dCTP pools [28] . The observation that TTP pool levels were decreased to a greater extent than dCTP levels may be explained by the fact that decreases in TTP may also be effected through inhibition of thymidine kinase activity, as described in the preceding paragraph. In addition, cellular accumulation of BrdUMP may result in inhibition of thymidylate synthetase activity, as reported for bacterial sources of this enzyme [29, 30] . Thus. there are potentially three mechanisms by which TTP pool levels can be decreased in glioblastoma cells, whereas dCTP pools appear to be decreased through only one mechanism.
To our knowledge, there has been only one previous report describing a reduction in the cellular TTP pool in response to BUdR [31] . Using Friend leukemia cells, it was demonstrated that 4 PM BUdR (in the presence of 1 mM butyric acid) reduced the TTP pools to approximately 50% of control within 30min and sustained that reduced nucleotide level for at least 6 hr. The results presented here illustrate that this reduction in TTP occurs with BUdR treatment in the U251 glioblastoma cells (in the absence of other additives). In addition, the data in Figs. 2 and 3 extend the previous results by demonstrating that the reduction in the TTP pool was dependent upon the BUdR concentration and, furthermore, that this effect was readily reversible upon washout of BUdR. In contrast to the results presented here, the data from the Friend leukemia cells demonstrated that there was little, if any, change in the dCTP pool in response to BUdR, while a 2-fold increase in dATP was noted. Thus, these data indicate that nucleotide pool changes mediated by BUdR are cell line specific and emphasize the necessity to define these alterations for each cell line under study. Although the reduction in TTP level in response to BUdR has important implications for the antitumor and radiosensitizing properties of the thymidine analog (as discussed below), little information exists on this effect, which may be explained by a couple of observations. First, many investigators employ the DNA polymerase assay to measure the levels of cellular deoxyribonucleotides, and it has been shown that this assay cannot distinguish between BrdUTP and TTP [32] . Thus, TTP levels were not measured in many studies of BUdR effects on nucleotide pools. Second, it was recognized more than 30 years ago that BrdUMP incorporation into DNA could be enhanced by decreasing the endogenous level of the competing TTP pool [3] . Thus, many studies examining the biologic effects of BUdR also employ inhibitors of TTP synthesis, such as FUdR. In such studies, depression of TTP pools is expected and attributed to the effects of the inhibitor of TTP synthesis. The data presented in this paper demonstrate that, in addition to the depression of cellular dCTP pools, BUdR induces an even more prominent reduction in the endogenous TTP level. This effect should be taken into consideration when adding BUdR and FUdR in combination since, at high levels of BUdR, the reduction in TTP pools may not be enhanced by FUdR. Indeed, Mancini et al. [ll] demonstrated that, in the D-54 glioblastoma cell line, BrdUMP incorporation into DNA could be enhanced by FUdR at concentrations of BUdR less than 10 PM, but at higher BUdR concentrations this effect was abolished. Experiments are underway to determine whether FUdR reduced the TTP pool levels at low but not high BUdR concentrations.
The BUdR-induced decrease in TTP pools has a dual beneficial effect on the incorporation of BrdUMP into DNA. As discussed above, depression of the endogenous TTP pool may increase the phosphorylation of BUdR, thus increasing the amount of precursor available for DNA incorporation. Furthermore, a reduction in cellular 'ITP decreases the concentration of the natural competitor of BrdUTP for the replicative DNA polymerases which should enhance the incorporation of BrdUMP into DNA. Considering that the reduction in 'ITP pools became more profound as the BUdR concentration was increased, it may be possible to administer BUdR at a concentration that would suppress the TTP pool to an undetectable level. However, at least 10% of the control level of TI'P remained in the cell in the presence of 100 PM BUdR, a highly cytotoxic concentration that is impractical to achieve clinically [l, 2, 8, 111. Thus, it would be most desirable to employ a second agent to effect an efficient decrease in endogenous TTP pools with the goal of enhancing BrdUMP incorporation into DNA at less toxic BUdR concentrations. The thymidylate synthetase inhibitor FUdR is a logical choice of agents to use since it can decrease cellular TTP pools at concentrations which do not appear to be toxic [30, 33] . However, data presented in this paper demonstrated that 10nM FUdR was unable to effect a decrease in the endogenous TTP pools in the U251 cell line either by itself or in the presence of BUdR. Consequently, BrdUMP incorporation into cellular DNA was not enhanced by the simultaneous administration of FUdR. A previous report indicated that concentrations of FUdR up to 25 nM were unable to enhance BrdUMP incorporation into U251 cell DNA [ll] . The failure of 10 nM FUdR to decrease TTP pools is most likely due to a lack of inhibition of thymidylate synthetase, for which there may be several explanations. FUdR requires phosphorylation to its 5'-monophosphate, FdUMP, which must then combine with thymidylate synthetase and a reduced folate cofactor in order to inhibit the enzyme [30, 33] . Hence, inadequate accumulation of FdUMP (possibly due to high cellular thymidine levels) or too little endogenous folate could prevent formation of the inhibitory complex. Alternatively, these cells may possess high levels of thymidylate synthetase or an altered form of the enzyme which is insensitive to inhibition by FdUMP. These hypotheses are presently under investigation.
While incorporation of BrdUMP into cellular DNA appears to be necessary for the antitumor and radiation sensitizing effects of BUdR, it is not known whether the overall level of incorporation of BrdUMP or perhaps its misincorporation for a nucleotide other than thymidylate results in its biologic effects. These two types of incorporation have been considered in detail in studies of the mutagenic activity of BUdR [25, . Although some investigators believe that mutagenesis is proportional to the total amount of BrdUMP incorporated into DNA [34] , other data indicate that the less frequently occurring substitution of BrdUMP for dCMP is the critical mutagenic event [25, 35] . If the antitumor and/or radiosensitizing effects are due to the overall level of BrdUMP incorporation into DNA, then reducing the cellular concentration of TTP will be crucial for enhancing BrdUMP incorporation.
However, if misincorporation of BrdUMP for dCMP is critical for its biologic effects, then it will be more important to reduce the endogenous dCTP pools to increase the likelihood that this type of misincorporation will occur. Hence it is necessary to distinguish which of these biochemical events is responsible for the antitumor and radiosensitizing effects of BUdR so that this information can be exploited in designing optimal chemotherapeutic protocols for this agent.
